Shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) rose 4.6% during trading on Friday . The company traded as high as $21.98 and last traded at $21.97, with a volume of 219,832 shares. The stock had previously closed at $21.00.

A number of research firms have recently issued reports on ENTA. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Vetr downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 price target on the stock. in a research note on Monday, April 25th. Finally, JMP Securities downgraded Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 28th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $28.58.

The stock has a market cap of $426.34 million and a PE ratio of 13.22. The stock has a 50-day moving average price of $22.55 and a 200-day moving average price of $26.13.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by $0.19. The company earned $13 million during the quarter, compared to analysts’ expectations of $16.80 million. The business’s revenue for the quarter was down 77.4% compared to the same quarter last year. During the same period last year, the firm earned $1.49 EPS. Analysts predict that Enanta Pharmaceuticals Inc. will post $0.98 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in ENTA. Schroder Investment Management Group raised its stake in shares of Enanta Pharmaceuticals by 91.8% in the fourth quarter. Schroder Investment Management Group now owns 439,303 shares of the company’s stock worth $14,506,000 after buying an additional 210,303 shares during the last quarter. First Trust Advisors LP bought a new stake in Enanta Pharmaceuticals during the fourth quarter worth $1,374,000. Matarin Capital Management LLC bought a new stake in Enanta Pharmaceuticals during the fourth quarter worth $4,644,000. Cornerstone Capital Management Holdings LLC. raised its stake in Enanta Pharmaceuticals by 114.7% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 32,851 shares of the company’s stock worth $1,085,000 after buying an additional 17,551 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in Enanta Pharmaceuticals by 8.0% in the fourth quarter. New York State Common Retirement Fund now owns 133,569 shares of the company’s stock worth $4,410,000 after buying an additional 9,871 shares in the last quarter.

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.